Kidney repair cells enter first human safety trial for diabetic kidney disease
NCT ID NCT07275788
First seen Jan 05, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This early-stage study is testing a new cell therapy called REGEND003 in 15 people with type 2 diabetes and chronic kidney disease. The treatment uses special kidney cells that may help repair kidney damage. The main goal is to check if the therapy is safe and tolerable, not yet to prove it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) AND CHRONIC KIDNEY DISEASE (CKD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Tongji Hospital
RECRUITINGShanghai, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.